Deals channel feed

In wake of mas­sive year-over-year growth, Mod­er­na re­serves its buy­ers seat at the glob­al deals ta­ble

4 years ago
Pharma

Novotech ex­tends arms in­to US with ac­qui­si­tion of a South Car­oli­na CRO

4 years ago
Outsourcing
Pharma

An up­start pro­tein degra­da­tion con­tender adds Mer­ck KGaA and Bris­tol My­ers to its list of Big Phar­ma back­ers

4 years ago
Pharma

As Bio­gen hunts for a turn­around CEO, ex­ecs sketch out a hazy look at an un­cer­tain new fu­ture

4 years ago
Bioregnum

Genen­tech-part­nered Gen­e­sis Ther­a­peu­tics inks newest AI dis­cov­ery deal with Eli Lil­ly

4 years ago
AI

GSK beat six oth­er com­pa­nies to the Sier­ra deal ta­ble and pre­vailed af­ter ini­tial $46 per share bid

4 years ago
Pharma

Biotech’s biggest in­vestor is prep­ping a whop­ping $4.75B wa­ger on the fu­ture of the in­dus­try

4 years ago

Gilead joins a line­up of Big Phar­ma part­ners bet­ting big on TriN­KETs, with a $300M cash ante to get start­ed on a 5T4

4 years ago
Bioregnum

Fake news? Nar­can mak­er forced to re­fute li­cens­ing deal af­ter wire ser­vice ap­par­ent­ly duped by false an­nounce­ment

4 years ago
R&D

As its slide stretch­es in­to a sec­ond year, Zymeworks faces takeover bid

4 years ago
Financing

Big Phar­ma CEOs as­sess the BD land­scape in biotech: Al­bert Bourla is stay­ing fo­cused on 2025-2030

4 years ago
Pharma

More mol­e­c­u­lar glue: Plex­i­um pens Ab­b­Vie pact months af­ter Am­gen deal

4 years ago

Cal­adrius’ 16-year rocky his­to­ry bends again in Cend merg­er; Af­ter Cel­lec­tis, Chi­na JV pacts, Cy­tovia inks SPAC deal

4 years ago
Financing
Startups

Am­gen kicks back I/O drug at cen­ter of $500M deal, leav­ing biotech part­ner alone to pon­der next steps

4 years ago

Sanofi of­floads French rights for an­tipsy­chot­ic to neigh­bor­ing phar­ma

4 years ago
Pharma

Vi­vo Cap­i­tal pitch­es $60M to bring Ar­row­head­'s RNAi meds to Chi­na via joint ven­ture

4 years ago
China

Sanofi of­floads two late-stage drugs to vir­tu­al­ly un­known neu­ro and psy­che­del­ic biotech

4 years ago
R&D

FTC re­quires Hik­ma to let go of steroid drug as part of $375M ac­qui­si­tion of Custopharm

4 years ago
Pharma

'Tim­ing could­n't be bet­ter': An ex-gener­ics mak­er goes SPAC route with blank check in­tend­ed for sports mar­ket

4 years ago
Financing
Startups

Re­gen­eron buys Art Krieg’s biotech start­up for a dis­count price, boost­ing I/O pipeline

4 years ago
R&D

Hit by 2 more flops, Bris­tol My­ers and Nek­tar wind down IL-2/PD-1 pro­gram at the cen­ter of $3.6B deal

4 years ago

Tiny Ok­la­homa com­pa­ny gets the eye of Boehringer In­gel­heim, sign­ing deal for re­gen­er­a­tive hear­ing loss treat­ment

4 years ago
Startups
R&D

In bid to re­make it­self af­ter pan­cre­at­ic can­cer flop, Halozyme ac­quires Antares and its drug de­liv­ery tech for $960M

4 years ago

From $3M to $1.9B: Glax­o­SmithK­line in­serts dis­card­ed Gilead drug in­to late-stage port­fo­lio, buy­ing out the turn­around crew at Sier­ra

4 years ago
First page Previous page 59606162636465 Next page Last page
A service from the Financial Times